Coronial
VIChospital

Finding into death of Graeme Harold Griffiths

Deceased

Graeme Harold Griffiths

Demographics

65y, male

Coroner

Deputy State Coroner Paresa Spanos

Date of death

2015-08-26

Finding date

2017-11-20

Cause of death

Severe neutropenic sepsis and multi-organ failure secondary to severe mucositis and probable DPD deficiency in the setting of T3 rectal carcinoma

AI-generated summary

A 65-year-old man with stage 3 rectal cancer died from severe neutropenic sepsis and multi-organ failure secondary to probable dihydropyrimidine dehydrogenase (DPD) deficiency when treated with capecitabine chemotherapy. He developed severe mucositis and systemic toxicity within days of commencing treatment. While the coroner found the clinical management appropriate by 2015 standards, the case highlights that DPD deficiency testing was not routine practice in Australia at the time, nor was a specific antidote available. The coroner noted emerging international practices in pre-treatment DPD testing and recommended that oncology groups consider adopting this as standard care, and that governments expedite access to the newly-available antidote Vistogard.

AI-generated summary and tagging — may contain inaccuracies; refer to original finding for legal purposes. Report an inaccuracy.

Specialties

oncologyradiation oncologycolorectal surgeryintensive care

Error types

delay

Drugs involved

capecitabine5-fluorouraciloxycodone

Clinical conditions

rectal carcinomaneutropenic sepsismulti-organ failuresevere mucositisenterocolitisDPD deficiencyseptic shock

Procedures

colonoscopyMRI rectumCT chest/abdomen/pelvischemotherapy administrationradiotherapyexploratory laparotomyintubation

Contributing factors

  • Probable dihydropyrimidine dehydrogenase (DPD) deficiency preventing metabolisation of capecitabine
  • Severe mucositis and gastrointestinal toxicity from 5-FU based chemotherapy
  • Lack of pre-treatment DPD deficiency screening (not standard practice in 2015)
  • Delayed recognition of severity of adverse reaction despite telephone consultations

Coroner's recommendations

  1. That the Medical Oncology Group of Australia consider whether testing for DPD deficiency should be standard care for patients proposed to be commenced on 5-FU chemotherapy treatment
  2. That the Federal and Victorian Governments expedite the agreement for a single national repository for the oral antidote to 5-FU, Vistogard
  3. That the Peter MacCallum Cancer Centre agree to establish and maintain a national repository for Vistogard
Full text

Source and disclaimer

This page reproduces or summarises information from publicly available findings published by Australian coroners' courts. Coronial is an independent educational resource and is not affiliated with, endorsed by, or acting on behalf of any coronial court or government body.

Content may be incomplete, reformatted, or summarised. Some material may have been redacted or restricted by court order or privacy requirements. Always refer to the original court publication for the authoritative record.

Copyright in original materials remains with the relevant government jurisdiction. AI-generated summaries and tagging are for educational purposes only, may contain inaccuracies, and must not be treated as legal documents. We welcome feedback for correction — report an inaccuracy here.